Total Payments
$5,266
2024 Payments
$785.28
Companies
27
Transactions
229
Medicare Patients
4,220
Medicare Billing
$5.0M
Payment Breakdown by Category
Food & Beverage$5,141 (97.6%)
Education$124.37 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,141 | 226 | 97.6% |
| Education | $124.37 | 3 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,071 | 36 | $0 (2024) |
| Amgen Inc. | $638.76 | 41 | $0 (2024) |
| Celgene Corporation | $475.29 | 18 | $0 (2019) |
| Genentech USA, Inc. | $457.62 | 23 | $0 (2024) |
| Janssen Biotech, Inc. | $446.85 | 13 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $299.78 | 12 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $274.78 | 9 | $0 (2024) |
| GlaxoSmithKline, LLC. | $269.97 | 12 | $0 (2023) |
| PFIZER INC. | $269.59 | 15 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $215.47 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $785.28 | 37 | ABBVIE INC. ($287.35) |
| 2023 | $874.93 | 29 | ABBVIE INC. ($232.24) |
| 2022 | $359.65 | 19 | Amgen Inc. ($69.00) |
| 2021 | $161.63 | 9 | GlaxoSmithKline, LLC. ($55.75) |
| 2020 | $443.82 | 24 | Amgen Inc. ($198.72) |
| 2019 | $1,139 | 43 | AbbVie, Inc. ($252.10) |
| 2018 | $607.68 | 27 | Celgene Corporation ($297.70) |
| 2017 | $894.06 | 41 | Genentech USA, Inc. ($274.29) |
All Payment Transactions
229 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/21/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Food and Beverage | In-kind items and services | $109.80 | General |
| Category: Immunology | ||||||
| 10/08/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $93.80 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $5.98 | General |
| Category: IMMUNOLOGY | ||||||
| 09/27/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.40 | General |
| Category: IMMUNOLOGY | ||||||
| 09/24/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $7.61 | General |
| Category: Inflammation | ||||||
| 09/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: IMMUNOLOGY | ||||||
| 09/16/2024 | Fresenius Kabi USA, LLC | — | Food and Beverage | In-kind items and services | $22.19 | General |
| 09/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $14.21 | General |
| Category: IMMUNOLOGY | ||||||
| 08/26/2024 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $30.95 | General |
| Category: Immunology | ||||||
| 08/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $5.93 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $7.27 | General |
| Category: Inflammation | ||||||
| 08/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.17 | General |
| Category: IMMUNOLOGY | ||||||
| 07/29/2024 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: Immunology | ||||||
| 07/26/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $125.66 | General |
| Category: IMMUNOLOGY | ||||||
| 07/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.28 | General |
| Category: IMMUNOLOGY | ||||||
| 07/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.19 | General |
| Category: IMMUNOLOGY | ||||||
| 07/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: IMMUNOLOGY | ||||||
| 07/15/2024 | Organon Llc | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: INFLIXIMAB | ||||||
| 06/27/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.34 | General |
| Category: IMMUNOLOGY | ||||||
| 06/20/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $7.92 | General |
| Category: Inflammation | ||||||
| 06/08/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 05/25/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Rare Disease | ||||||
| 05/24/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $4.51 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/21/2024 | ABBVIE INC. | HUMIRA (Biological), RINVOQ | Food and Beverage | In-kind items and services | $8.57 | General |
| Category: IMMUNOLOGY | ||||||
| 05/14/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $6.61 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 908 | 65,088 | $3.4M | $857,550 |
| 2022 | 22 | 1,120 | 74,722 | $4.7M | $1.2M |
| 2021 | 20 | 1,104 | 95,067 | $4.7M | $1.4M |
| 2020 | 22 | 1,088 | 65,380 | $4.4M | $1.5M |
Total Patients
4,220
Total Services
300,257
Medicare Billing
$5.0M
Procedure Codes
83
All Medicare Procedures & Services
83 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 31 | 7,587 | $849,969 | $248,548 | 29.2% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 13 | 2,250 | $418,200 | $143,095 | 34.2% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 40 | 4,912 | $682,729 | $109,852 | 16.1% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 13 | 19,461 | $238,072 | $90,469 | 38.0% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 11 | 21,200 | $401,200 | $82,757 | 20.6% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 18 | 6,474 | $342,948 | $68,090 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 169 | 330 | $113,444 | $28,903 | 25.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 118 | 298 | $143,134 | $26,335 | 18.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 1,380 | $56,040 | $25,179 | 44.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 181 | 310 | $68,888 | $17,300 | 25.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 34 | 166 | $45,619 | $8,733 | 19.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 60 | 183 | $19,555 | $3,677 | 18.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $6,504 | $1,564 | 24.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 35 | 132 | $11,212 | $1,558 | 13.9% |
| 20600 | Aspiration and/or injection of fluid from small joint | Office | 2023 | 11 | 16 | $2,876 | $625.38 | 21.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 41 | 54 | $756.00 | $453.60 | 60.0% |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | Office | 2023 | 34 | 66 | $957.00 | $206.98 | 21.6% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 33 | 141 | $1,640 | $108.19 | 6.6% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 36 | 114 | $566.50 | $94.53 | 16.7% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 34 | 12,630 | $1.4M | $433,793 | 30.1% |
| J9312 | Injection, rituximab, 10 mg | Office | 2022 | 17 | 3,451 | $573,300 | $209,771 | 36.6% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 45 | 7,338 | $1.2M | $187,952 | 16.0% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2022 | 17 | 37,842 | $447,384 | $172,846 | 38.6% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 21 | 9,100 | $473,200 | $107,269 | 22.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 19 | 1,800 | $72,000 | $30,435 | 42.3% |
About Dr. William Maier, MD
Dr. William Maier, MD is a Rheumatology healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790735561.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Maier, MD has received a total of $5,266 in payments from pharmaceutical and medical device companies, with $785.28 received in 2024. These payments were reported across 229 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($5,141).
As a Medicare-enrolled provider, Maier has provided services to 4,220 Medicare beneficiaries, totaling 300,257 services with total Medicare billing of $5.0M. Data is available for 4 years (2020–2023), covering 83 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Eugene, OR
- Active Since 05/11/2006
- Last Updated 09/15/2010
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1790735561
Products in Payments
- Otezla (Drug) $453.68
- RINVOQ (Biological) $362.50
- Humira (Biological) $288.62
- KRYSTEXXA (Biological) $272.91
- SIMPONI ARIA (Biological) $261.80
- Rituxan (Biological) $243.44
- BENLYSTA (Biological) $220.24
- ORENCIA (Biological) $215.47
- COSENTYX (Biological) $215.09
- Actemra (Biological) $200.96
- EVENITY (Biological) $200.89
- SKYRIZI (Biological) $177.31
- KEVZARA (Biological) $174.35
- Cimzia (Drug) $158.52
- KEVZARA SARILUMAB INJECTION (Biological) $156.85
- Enbrel (Biological) $142.61
- TREMFYA (Drug) $122.19
- Rinvoq (Biological) $119.14
- PAXLOVID (Drug) $101.60
- XELJANZ (Drug) $98.79
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Eugene
Dr. Diman Lamichhane, Md, MD
Rheumatology — Payments: $20,004
Rheumatology $20,004
Sidney Cassell, Md, MD
Rheumatology — Payments: $1,818
Rheumatology $1,818
Simona Braun, Md, MD
Rheumatology — Payments: $1,765
Rheumatology $1,765
Sarah Cassell
Rheumatology — Payments: $1,444
Rheumatology $1,444
Hesham Elmergawy, M.d, M.D
Rheumatology — Payments: $879.81
Rheumatology $879.81
Dr. Norman Hudson, Md, MD
Rheumatology
Rheumatology